Last reviewed · How we verify
LBAL
LBAL is a therapeutic agent in development by LG Life Sciences, currently in phase 3 clinical trials.
At a glance
| Generic name | LBAL |
|---|---|
| Also known as | Adalimumab |
| Sponsor | LG Life Sciences |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited publicly available information exists regarding LBAL's specific mechanism of action. As a phase 3 candidate from LG Life Sciences, it represents an investigational compound under active clinical evaluation, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy (PHASE3)
- Pharmacokinetics and Safety Study of LBAL in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBAL CI brief — competitive landscape report
- LBAL updates RSS · CI watch RSS
- LG Life Sciences portfolio CI